Harrow Comes Out of Allergan Lawsuit Unscathed

Contributed Opinion
  ()
Sector expert Daniel Carlson offers his take on the recent jury decision, calling it "very positive." read more >

Why Did ImmunoGen Plummet 32%?

  ()
This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. read more >

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer

Research Report
  ()
An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. read more >

Women's Wellness Device Developer Posts In-Line Quarter, Catalysts Looming

Research Report
  ()
A review of this Colorado company's first numbers of the year was provided in a Ladenburg Thalmann report. read more >
News Update

Biopharma Releases Preliminary Data from Alcoholic Hepatitis Study

News Update
  ()
The results compare favorably to those of the historical control group. read more >

Price Target Raised on Biopharma Ahead of Leukemia Trial Update

Research Report
  ()
The expected data and their implications were addressed in a ROTH Capital Partners report. read more >

Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million

Research Report
  ()
The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. read more >

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Research Report
  ()
Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. read more >

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

Research Report
  ()
A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. read more >
News Update

Firm's AR E-Commerce Solutions to Be Marketed, Sold to Dispensaries

News Update
  ()
With the signing of a reseller agreement, the tech firm continues to penetrate Canada's burgeoning legal cannabis industry. read more >

Expert Investing Ideas

"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company


"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"DRRX's Posimir comes back in play."

–Ed Arce, H.C. Wainwright & Co.


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical
News Update

Health Tech Firm to Pilot Artificial Intelligence-Powered Patient Monitoring Tool

News Update
  ()
This effort is one way the company can innovatively offer patients care. read more >

'Undervalued' Biopharma Features Robust Pipeline, Future Upside

Research Report
  ()
The case for investing in this company was made in an H.C. Wainwright & Co. report. read more >

California Gold Mining Full Speed Ahead in Hemp

Contributed Opinion
  ()
Peter Epstein of Epstein Research provides an update on a mining exploration company that is diversifying into the hemp market. read more >

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial

Research Report
  ()
Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. read more >